Expert computational design for siRNA, ASO, CRISPR, Nanobody, Antibody, and Antibody-Oligonucleotide Conjugates — cutting your discovery timeline by up to 60%.
From oligonucleotide sequence to antibody structure — we deliver computation-first designs that reduce wet-lab cost and accelerate IND readiness.
Potent gene-silencing sequences with comprehensive off-target profiling and chemical modification strategies.
RNA TherapeuticssgRNA design with PAM analysis, on-target scoring, and full off-target prediction for base and prime editing.
Gene EditingVHH domain design, CDR optimization, humanization, and binding affinity prediction via molecular dynamics.
Single-domain AbFull mAb design pipeline — VH/VL framework selection, humanization, bispecifics, and developability scoring.
BiologicsAntibody-Oligonucleotide Conjugate design — linker optimization, conjugation site prediction, and dual-payload modeling.
Conjugate TherapyGene prioritization, druggability analysis, pathway enrichment, and multi-omics integration for target ID.
Drug DiscoveryVirtual screening, molecular docking, ADMET profiling, and hit-to-lead optimisation for small molecule drug discovery.
CADDHomology modelling, biosimilar comparability, immunogenicity prediction, and biologic developability assessment.
BiologicsA streamlined engagement designed to get you validated candidates fast.
Beyond industry-standard tools, GENsilica has developed proprietary computational pipelines for each therapeutic modality — refined through hundreds of design cycles to maximise candidate quality, reduce off-target risk, and cut design time significantly.
These pipelines are not available commercially. They represent GENsilica's core intellectual property and the reason our lead candidates consistently outperform off-the-shelf design approaches.
End-to-end computational design across 8 therapeutic modalities — small molecules, large biologics, RNA therapeutics, gene editing, and next-gen conjugates — delivered with pharma-grade rigour and startup-friendly speed.
Potent, selective RNA silencing sequences with full off-target profiling and delivery optimization
Precision sgRNA design with PAM site analysis, on-target scoring, and comprehensive off-target prediction
Single-domain antibody design, CDR optimization, humanization, and affinity prediction via MD simulation
Full monoclonal antibody design — VH/VL framework selection, humanization, bispecifics, and developability
Next-generation dual-payload therapy combining antibody targeting with oligonucleotide silencing
Computer-aided drug design for small molecule lead identification, virtual screening, and hit-to-lead optimisation
Computational development for biologics, proteins, peptides, and biosimilar comparability assessments
Every engagement at GENsilica begins with a single commitment — to understand your science as deeply as you do. We bring computational precision; you bring biological vision. Together, we move faster.
Not sure which therapeutic modality fits your target? We provide an independent scientific assessment — evaluating your target biology, modality feasibility, competitive landscape, and computational design pathway — before you commit to any development spend. Think of it as your scientific second opinion from a specialist.
We are computational biologists on a mission to make next-generation therapeutic design accessible to every biotech company, regardless of size.
GENsilica is a specialized computational biology consultancy headquartered in India. We provide expert in-silico design services for the most powerful therapeutic modalities in modern drug development — siRNA, ASO, CRISPR, Nanobody, Antibody, and AOC.
Our founder brings deep hands-on expertise across all six of these modalities, with experience spanning early-stage target identification through lead optimization and regulatory documentation. We have worked on projects targeting oncology, rare disease, neurological disorders, and infectious disease.
We believe the future of drug discovery is computational-first. By building robust in-silico pipelines before any molecule touches a lab bench, we help our clients reduce failures, save millions in wet-lab costs, and reach IND faster.
Whether you are a venture-backed biotech startup with a novel target, a large pharma CRO looking to outsource specialized modalities, or an academic lab transitioning towards translation — GENsilica is your dedicated computational design partner.
siRNA, ASO, saRNA design with chemical modification and delivery optimization expertise.
CRISPR/Cas9, base editing, and prime editing guide design with rigorous off-target analysis.
mAb, bispecific, nanobody (VHH), and antibody fragment design and humanization.
AOC design combining antibody precision targeting with oligonucleotide gene silencing.
We leverage the world's most validated computational tools — the same platforms used by leading pharma companies and academic institutions globally.
We never sacrifice scientific rigor for fast turnaround. Every design decision is backed by evidence, validated by multiple computational methods.
We work as an extension of your team — learning your pipeline, your targets, and your regulatory requirements to deliver exactly what you need.
We sign NDAs before any scientific discussion. Your targets, data, and IP are protected at every stage of our engagement.
Every deliverable includes full methodology, scoring rationale, and candidate rankings — so you understand exactly why we selected each lead.
India-based, internationally competitive. We bring world-class computational biology to clients across Asia, Europe, and North America.
We stay at the cutting edge — continuously integrating the latest AI tools like AlphaFold, RFdiffusion, and large language models for biology.
Real-world design challenges solved with computational precision — from siRNA lead generation to CRISPR off-target remediation.
Designed a panel of 15 siRNA candidates targeting KRAS G12D mutation in non-small cell lung cancer. Full off-target profiling against the human transcriptome identified 3 highly selective leads with >85% predicted silencing efficiency.
A client's initial sgRNA design for Duchenne muscular dystrophy showed 12 predicted off-target sites. Redesigned using optimized PAM sites and high-fidelity Cas9 variants, reducing off-targets to 0 predicted sites at comparable on-target score.
Humanized a camelid-derived anti-PD-L1 VHH domain while maintaining binding affinity. Molecular dynamics simulation predicted 2-fold improvement in binding ΔG through strategic CDR3 loop redesign. Delivered 6 humanized variants ranked by developability.
Designed an antibody-oligonucleotide conjugate targeting a blood-brain barrier receptor for CNS delivery of a gene-silencing ASO. Linker design optimized for lysosomal release, with predicted DAR of 2 and full stability analysis across pH 5–7.4.
Applied computer-aided drug design (CADD) to screen a virtual library of 50,000 small molecule compounds against a novel oncology kinase target. Molecular docking, ADMET prediction, and binding free energy calculations identified 8 high-confidence lead scaffolds for synthesis.
Performed in-silico structural and functional comparability analysis for a biosimilar monoclonal antibody candidate. Homology modelling, epitope mapping, and molecular dynamics simulations confirmed structural equivalence to the reference biologic within regulatory-accepted parameters.
Every project starts with a free 30-minute scientific consultation.
Every engagement begins with a free scientific consultation — no commitment, just a conversation about your therapeutic challenge.
We'll respond within 24 hours with a free initial assessment.